Kakkis Emil D., CEO of Ultragenyx Pharmaceutical RARE, has filed 0 purchases and 11 sales on the open market. Over the past 12 months that comes to a net sale of $1.2M. The latest trade was on 04/16.

KD

KD

Kakkis Emil D.

President & CEO

Company

Ultragenyx Pharmaceutical RARE

First filing

23/01/03

Trades

28 trades

Buys / sales

0 / 11

12-month net buying

−$1.2M

Last trade

04/16

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Ultragenyx PharmaceuticalRARE	Open-market sale	03/02	03/03	54,404 sh	$22.80	$1,240,411.2	−7.6%
Ultragenyx PharmaceuticalRARE	Open-market sale10b5-1 plan	25/02/28–25/03/03	25/03/04	98,434 sh2 trades	$42.20avg.	$4,153,571.4	No record
Ultragenyx PharmaceuticalRARE	Open-market sale10b5-1 plan	24/12/30	24/12/31	11,727 sh	$42.23	$495,231.21	−0.5%
Ultragenyx PharmaceuticalRARE	Open-market sale10b5-1 plan	24/12/10	24/12/11	8,273 sh	$50.00	$413,650	−0.4%
Ultragenyx PharmaceuticalRARE	Open-market sale10b5-1 plan	24/09/03	24/09/05	20,000 sh	$55.85	$1,117,000	−0.9%
Ultragenyx PharmaceuticalRARE	Open-market sale10b5-1 plan	24/08/06	24/08/07	20,000 sh	$50.17	$1,003,400	−0.9%
Ultragenyx PharmaceuticalRARE	Open-market sale	24/02/07	24/02/08	30,000 sh	$45.00	$1,350,000	−5.3%
Ultragenyx PharmaceuticalRARE	Open-market sale	23/12/29	24/01/02	30,000 sh	$47.87	$1,436,100	−5.0%
Ultragenyx PharmaceuticalRARE	Open-market sale	23/10/19	23/10/23	47,853 sh	$33.52	$1,604,032.56	−7.4%
Ultragenyx PharmaceuticalRARE	Open-market sale	22/12/30	23/01/03	19,582 sh	$45.57	$892,351.74	−3.5%